Based on the XTL Biopharmaceuticals Ltd ADR stock forecast from 0 analysts, the average analyst target price for XTL Biopharmaceuticals Ltd ADR is not available over the next 12 months. XTL Biopharmaceuticals Ltd ADR’s average analyst rating is not available. Stock Target Advisor’s own stock analysis of XTL Biopharmaceuticals Ltd ADR is Neutral, which is based on 4 positive signals and 4 negative signals. At the last closing, XTL Biopharmaceuticals Ltd ADR’s stock price was USD 1.13. XTL Biopharmaceuticals Ltd ADR’s stock price has changed by -5.83% over the past week, -9.60% over the past month and -64.13% over the last year.
No recent analyst target price found for XTL Biopharmaceuticals Ltd ADR
No recent average analyst rating found for XTL Biopharmaceuticals Ltd ADR
Company Overview XTL Biopharmaceuticals Ltd ADR
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. It has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was incorporated in 1993 and is headquartered in Ramat Gan, Israel. Read Less
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythem...Read More
Frequently Asked Questions About XTL Biopharmaceuticals Ltd ADR (XTLB) Stock
Stock Target Advisor's fundamental analysis for XTL Biopharmaceuticals Ltd ADR's stock is Neutral.
Unfortunately we do not have enough data on XTLB's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on XTLB's stock to indicate what its average analyst target is.
XTLB stock's Price/Earning ratio is 4.65.
Our analysis grades XTLB stock's Price / Earning ratio at F. This means that XTLB stock's Price/Earning ratio is above 48% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this XTLB may be fairly valued for its sector
The last closing price of XTLB's stock was USD 1.13.
The most recent market capitalization for XTLB is USD 0.01B.
Unfortunately we do not have enough analyst data on XTLB's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains XTL Biopharmaceuticals Ltd ADR's stock.
As per our most recent records XTL Biopharmaceuticals Ltd ADR has 0 Employees.
XTL Biopharmaceuticals Ltd ADR's registered address is 26 Ben-Gurion St., Ramat Gan, Israel, 5112001.
You can get more information about it from XTL Biopharmaceuticals Ltd ADR's website at https://www.xtlbio.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Superior risk adjusted returns
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
Superior return on equity
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
What not to like
High volatility
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About XTL Biopharmaceuticals Ltd ADR (XTLB) Stock
Stock Target Advisor's fundamental analysis for XTL Biopharmaceuticals Ltd ADR's stock is Neutral.
Unfortunately we do not have enough data on XTLB's stock to indicate if its a good dividend stock.
Unfortunately we do not have enough data on XTLB's stock to indicate what its average analyst target is.
XTLB stock's Price/Earning ratio is 4.65.
Our analysis grades XTLB stock's Price / Earning ratio at F. This means that XTLB stock's Price/Earning ratio is above 48% of the stocks in the Biotechnology sector in the NSD exchange.
Based on this XTLB may be fairly valued for its sector
The last closing price of XTLB's stock was USD 1.13.
The most recent market capitalization for XTLB is USD 0.01B.
Unfortunately we do not have enough analyst data on XTLB's stock to indicate whether its price will go up or not.
We can't find any ETFs which contains XTL Biopharmaceuticals Ltd ADR's stock.
As per our most recent records XTL Biopharmaceuticals Ltd ADR has 0 Employees.
XTL Biopharmaceuticals Ltd ADR's registered address is 26 Ben-Gurion St., Ramat Gan, Israel, 5112001.
You can get more information about it from XTL Biopharmaceuticals Ltd ADR's website at https://www.xtlbio.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for XTLB !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
